Please use this identifier to cite or link to this item:
Title: SARS CoV subunit vaccine: Antibodymediated neutralisation and enhancement
Authors: Jaume, M
Yip, MS
Kam, YW
Cheung, CY
Kien, F
Roberts, A
Li, PH
Dutry, I
Escriou, N
Daeron, M
Bruzzone, R
Subbarao, K
Peiris, JSM
Nal, B
Altmeyer, R
Keywords: SARS-CoV;Vaccine;Antibody;Spike-protein trimers;triSpike;Human haematopoietic cells
Issue Date: 2012
Citation: Hong Kong Medical Journal, 2012, 18 (SUPP2), pp. 31 - 36
Abstract: 1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).
ISSN: 1024-2708
Appears in Collections:Dept of Electronic and Computer Engineering Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf431.56 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.